Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Shanghai Pharmaceuticals Holding Co Ltd
Total Equity
Shanghai Pharmaceuticals Holding Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Total Equity
¥75.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Total Equity
¥80.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Total Equity
¥28.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Total Equity
¥18B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
20%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Total Equity
¥24.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
24%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Total Equity
¥18.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.
See Also
What is Shanghai Pharmaceuticals Holding Co Ltd's Total Equity?
Total Equity
75.8B
CNY
Based on the financial report for Sep 30, 2025, Shanghai Pharmaceuticals Holding Co Ltd's Total Equity amounts to 75.8B CNY.
What is Shanghai Pharmaceuticals Holding Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
10%
Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been 5% over the past three years , 11% over the past five years , and 10% over the past ten years .